Yaikwawong Metha, Jansarikit Laddawan, Jirawatnotai Siwanon, Chuengsamarn Somlak
Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Siriraj Center of Research Excellence for Precision Medicine and Systems, Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Nutr J. 2024 Oct 1;23(1):119. doi: 10.1186/s12937-024-01022-3.
Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression.
To assess the efficacy of improving type 2 diabetes (T2DM).
This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes.
All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention.
After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001.
A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial.
Thai clinical trials regentrify no.20140303003.
2型糖尿病（T2DM）是一种以胰岛素抵抗和胰岛素分泌受损为特征的慢性疾病，可导致血糖水平升高。姜黄素是一种从姜黄中提取的多酚类化合物，已显示出改善胰岛素敏感性和降低血糖水平的潜力，这可能有助于减轻2型糖尿病的进展。
评估姜黄素改善2型糖尿病（T2DM）的疗效。
本随机、双盲、安慰剂对照试验纳入了符合2型糖尿病标准的受试者（n = 272）。
所有受试者被随机分配接受姜黄素（1500毫克/天）或带有盲标签的安慰剂，为期12个月。为评估姜黄素治疗后T2DM的改善情况，在干预过程中的基线以及第3、6、9和12个月访视时监测体重、体重指数、空腹血糖、糖化血红蛋白A、β细胞功能（稳态模型评估[HOMA-β]）、胰岛素抵抗（HOMA-IR）、胰岛素、脂联素和瘦素。
治疗12个月后，姜黄素治疗组的空腹血糖显著降低（115.49对130.71；P < 0.05），糖化血红蛋白A也显著降低（6.12对6.47；P < 0.05）。此外，姜黄素治疗组的β细胞整体功能更好，HOMA-β更高（136.20对105.19；P < 0.01）。与安慰剂组相比，姜黄素治疗组的HOMA-IR水平更低（4.86对6.04；P < 0.001），脂联素水平更高（14.51对10.36；P < 0.001）。姜黄素治疗组的瘦素水平也更低（9.42对20.66；P < 0.001）。此外，体重指数降低（25.94对29.34），P值为0.001。
对2型糖尿病患者进行为期12个月的姜黄素干预显示出显著的降糖效果。姜黄素治疗似乎可改善β细胞的整体功能，降低胰岛素抵抗和体重，且不良反应非常轻微。姜黄素干预对肥胖的2型糖尿病患者可能有益。
泰国临床试验注册号：20140303003。
